| Parasitoses intestinais: uma revisão sobre seus aspectos sociais, epidemiológicos, clínicos e terapêuticos ECD Andrade, ICG Leite, VDO Rodrigues, MG Cesca Rev APS 13 (2), 231-40, 2010 | 292 | 2010 |
| HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer L de Moura Leite, MG Cesca, MC Tavares, DM Santana, EF Saldanha, ... Breast cancer research and treatment 190 (1), 155-163, 2021 | 158 | 2021 |
| HER2-positive advanced breast cancer treatment in 2020 MG Cesca, L Vian, S Cristóvão-Ferreira, N Pondé, E de Azambuja Cancer treatment reviews 88, 102033, 2020 | 125 | 2020 |
| Factors associated with lymphedema in patients with breast cancer DMF Paiva, ICG Leite, VO Rodrigues, MG Cesca Rev Bras Ginecol Obstet 33, 75-80, 2011 | 43* | 2011 |
| Prevalence of lymphedema in women undergoing treatment for breast cancer in a referral center in southeastern Brazil DMF Paiva, VO Rodrigues, MG Cesca, PV Palma, ICG Leite BMC women's health 13 (1), 6, 2013 | 31 | 2013 |
| Combined endocrine and targeted therapy in luminal breast cancer M Goldner, N Pandolfi, D Maciel, J Lima, S Sanches, N Ponde Expert review of anticancer therapy 21 (11), 1237-1251, 2021 | 25 | 2021 |
| Voice analysis after cancer treatment with organ preservation RJDS Campos, CTV Maciel, MG Cesca, ICG Leite Head & neck oncology 3 (1), 19, 2011 | 24 | 2011 |
| Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis AABA da Costa, ES Dos Santos, DP Cotrim, NC Pandolfi, MG Cesca, ... BMC cancer 19 (1), 1194, 2019 | 12 | 2019 |
| Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study LJC Oliveira, TBC Megid, DD Rosa, CAS Magliano, DX Assad, DF Argolo, ... Therapeutic Advances in Medical Oncology 14, 17588359221141760, 2022 | 10 | 2022 |
| HER2-low and gastric cancer: A prognostic biomarker? BCM Uchôa, R Pirolli, LB Mendes Gomes Siqueira, FGR Moura, ... Journal of Clinical Oncology 39 (15_suppl), e16086-e16086, 2021 | 5 | 2021 |
| Comparison of enzalutamide versus abiraterone in castration-resistant prostate cancer before docetaxel: Results of a propensity score-matched analysis. MG Cesca, MT Silveira, NC Pandolfi, TB Oliveira, JA Rinck, ... Journal of Clinical Oncology 37 (15_suppl), e16540-e16540, 2019 | 5 | 2019 |
| Cancer outcomes from a real-world cohort of patients eligible for adjuvant CDK4/6 inhibitors but without genomic risk for chemotherapy: A GBECAM multicenter retrospective study. LJC Oliveira, DD Rosa, A Katz, DA Suzuki, DF Argolo, SM Sanches, ... Journal of Clinical Oncology 42 (16_suppl), 540-540, 2024 | 3 | 2024 |
| Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study MG Cesca, E Ruiz-Garcia, R Weschenfelder, N D’Agustini, S Iseas, ... ecancermedicalscience 17, 1586, 2023 | 3 | 2023 |
| 220P Oral selective estrogen receptor degraders for metastatic hormone receptor-positive, HER2 negative breast cancer according to ESR1 mutation: A systematic review and meta … RGS Novello, M Lobo, MS Vilbert, SM Sanches, MG Cesca ESMO Open 8 (1), 2023 | 2 | 2023 |
| Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients F Pignataro-Oshiro, AB Figueiredo, NAL Galdino, KLP Morais, WO Dutra, ... Frontiers in Immunology 13, 1052104, 2023 | 2 | 2023 |
| Solitary fibrous tumor: A Brazilian cohort analysis. MG Cesca, CL Mello, T Felismino, MN Formiga, UR Nicolau, S Aguiar, ... Journal of Clinical Oncology 37 (15_suppl), 11068-11068, 2019 | 2 | 2019 |
| Real-world analysis of patients with triple-negative breast cancer and germline BRCA mutation undergoing neoadjuvant treatment following the keynote 522 protocol M Tavares, FC Balint, IM De Sousa, AC Marin Comini, MG Cesca, ... CLINICAL CANCER RESEARCH 31 (12), P50918-P50918, 2025 | 1 | 2025 |
| Loss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer ÁMC Caldas, WA Nunes, R Taboada, MG Cesca, JN Germano, ... ecancermedicalscience 18, 1666, 2024 | 1 | 2024 |
| 481P Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: a systematic review and meta-analysis of clinical trials MS Vilbert, DP Xavier, MG Cesca, LV Ravani, J Chamadoira, C Stecca, ... Annals of Oncology 34, S383, 2023 | 1 | 2023 |
| 353P Loss of CDX2 and high COX2 (PTGS2) expression in stage IV colorectal cancer A Caldas, WA Nunes, RG Taboada, MG Cesca, JN Germano, ... Annals of Oncology 33, S697, 2022 | 1 | 2022 |
Solange Moraes SanchesMédica Titular do Depto de Oncologia Clinica do Hospital AC CamargoVerified email at accamargo.org.br
